85 related articles for article (PubMed ID: 2452313)
1. Beta-adrenoreceptor antagonist potency and pharmacodynamics of ASL-8123, the primary acid metabolite of esmolol.
Shaffer JE; Quon CY; Gorczynski RJ
J Cardiovasc Pharmacol; 1988 Feb; 11(2):187-92. PubMed ID: 2452313
[TBL] [Abstract][Full Text] [Related]
2. Beta-blocking and hemodynamic effects of ASL-8052.
Gorczynski RJ; Murthy VS; Hwang TF
J Cardiovasc Pharmacol; 1984; 6(6):1548-59. PubMed ID: 6084788
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
Hicks PE; Cavero I; Manoury P; Lefevre-Borg F; Langer SZ
J Pharmacol Exp Ther; 1987 Sep; 242(3):1025-34. PubMed ID: 2888869
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics and onset of action of esmolol in anesthetized dogs.
Quon CY; Gorczynski RJ
J Pharmacol Exp Ther; 1986 Jun; 237(3):912-8. PubMed ID: 2872328
[TBL] [Abstract][Full Text] [Related]
5. Controlled beta-receptor blockade with flestolol: a novel ultrashort-acting beta-blocker.
Murthy VS; Hwang TF; Rosen LB; Gorczynski RJ
J Cardiovasc Pharmacol; 1987 Jan; 9(1):72-8. PubMed ID: 2434798
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of beta-adrenoceptor blocking efficacy of two formulations of esmolol in vivo and in vitro.
Tripathi CB; Bhattacharya P; Bhatt JD; Hemavathi KG
Indian J Physiol Pharmacol; 1999 Apr; 43(2):255-8. PubMed ID: 10365322
[TBL] [Abstract][Full Text] [Related]
7. Antiarrhythmic activity of esmolol (ASL-8052)--a novel ultra-short acting beta-adrenoreceptor blocking agent.
Klein G; Wirtzfeld A; Alt E; Steck J; Saunders R; Hulse J; Kartzinel R; Lee R; Laddu AR
Int J Clin Pharmacol Ther Toxicol; 1984 Feb; 22(2):112-7. PubMed ID: 6142005
[TBL] [Abstract][Full Text] [Related]
8. High isoproterenol doses are required to activate beta3-adrenoceptor-mediated functions in dogs.
Pelat M; Verwaerde P; Galitzky J; Lafontan M; Berlan M; Senard JM; Montastruc JL
J Pharmacol Exp Ther; 2003 Jan; 304(1):246-53. PubMed ID: 12490598
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of ASL-8052, a novel beta-adrenergic receptor antagonist with an ultrashort duration of action.
Gorczynski RJ; Shaffer JE; Lee RJ
J Cardiovasc Pharmacol; 1983; 5(4):668-77. PubMed ID: 6193366
[TBL] [Abstract][Full Text] [Related]
10. Beta 1-selectivity of bisoprolol, a new beta-adrenoceptor antagonist, in anesthetized dogs and guinea pigs.
Schliep HJ; Harting J
J Cardiovasc Pharmacol; 1984; 6(6):1156-60. PubMed ID: 6084774
[TBL] [Abstract][Full Text] [Related]
11. Intravenous atenolol and esmolol maintain the protective effect of ischemic preconditioning in vivo.
Iliodromitis EK; Tasouli A; Andreadou I; Bofilis E; Zoga A; Cokkinos P; Kremastinos DT
Eur J Pharmacol; 2004 Sep; 499(1-2):163-9. PubMed ID: 15363963
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular pharmacology of ASL-7022. III. Peripheral vascular adrenergic mechanisms.
Gorczynski RJ; Reynolds RD
J Pharmacol Exp Ther; 1985 Mar; 232(3):629-35. PubMed ID: 2857783
[TBL] [Abstract][Full Text] [Related]
13. The antagonist and partial beta agonist properties of celiprolol in isolated rat cardiac tissue.
Smith RD; Cobuzzi A; Wolf PS; Pruss TP
Res Commun Chem Pathol Pharmacol; 1986 Feb; 51(2):147-61. PubMed ID: 2870551
[TBL] [Abstract][Full Text] [Related]
14. Effects of nebivolol, atenolol and propranolol on in vivo cardiovascular and metabolic responses to isoproterenol in dogs.
Bowden CR; Marchione CS
J Pharmacol Exp Ther; 1989 Nov; 251(2):599-605. PubMed ID: 2572694
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological studies of mabuterol, a new selective beta 2-stimulant. II: Effects on the cardiovascular system and smooth muscle organs.
Osada E; Murai T; Ishizaka Y; Sanai K
Arzneimittelforschung; 1984; 34(11A):1641-51. PubMed ID: 6152157
[TBL] [Abstract][Full Text] [Related]
16. Selective beta(1)-adrenoreceptor blocking activity of newly synthesized acyl amino-substituted aryloxypropanolamine derivatives, DPJ 955 and DPJ 890, in rats.
Nandakumar K; Bansal SK; Singh R; Bodhankar SL; Jindal DP; Coumar MS; Balaraman R; Bhardwaj SH
J Pharm Pharmacol; 2005 Apr; 57(4):515-9. PubMed ID: 15831214
[TBL] [Abstract][Full Text] [Related]
17. Esmolol for potentiation of nitroprusside-induced hypotension: impact on the cardiovascular, adrenergic, and renin-angiotensin systems in man.
Edmondson R; Del Valle O; Shah N; Wong G; Dwyer D; Matarazzo D; Thorne A; Coffey C; Bedford R
Anesth Analg; 1989 Aug; 69(2):202-6. PubMed ID: 2569849
[TBL] [Abstract][Full Text] [Related]
18. L-3,4-(3-3,4-dimethoxyphenethylamino-2-hydroxypropoxy)-phenyl- crotonic acid nitrile.HCl (Hoe 224), a beta-blocking agent with high beta 1-selectivity.
Lindner E
Arzneimittelforschung; 1984; 34(3):270-6. PubMed ID: 6145430
[TBL] [Abstract][Full Text] [Related]
19. Beta-blocking potency of mepindolol and pindolol against isoproterenol-induced inotropic and chronotropic responses in guinea pig atria.
Anderson WG
J Cardiovasc Pharmacol; 1984; 6(1):7-11. PubMed ID: 6199615
[TBL] [Abstract][Full Text] [Related]
20. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
Barbier GH; Shettigar UR; Appunn DO
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
